Psyence Biomedical (PBM) Competitors

Psyence Biomedical logo
$2.86 +0.35 (+13.94%)
Closing price 11/19/2026 04:00 PM Eastern
Extended Trading
$2.87 +0.01 (+0.35%)
As of 08:18 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

PBM vs. CRVO, ABVC, PLRZ, MIRA, and IXHL

Should you buy Psyence Biomedical stock or one of its competitors? Psyence Biomedical's main competitors and comparable companies include CervoMed (CRVO), ABVC BioPharma (ABVC), Polyrizon (PLRZ), MIRA Pharmaceuticals (MIRA), and Incannex Healthcare (IXHL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Psyence Biomedical compare to CervoMed?

CervoMed (NASDAQ:CRVO) and Psyence Biomedical (NASDAQ:PBM) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, media sentiment, valuation, risk and earnings.

Psyence Biomedical has lower revenue, but higher earnings than CervoMed. CervoMed is trading at a lower price-to-earnings ratio than Psyence Biomedical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CervoMed$4.01M5.02-$26.97M-$2.77N/A
Psyence BiomedicalN/AN/A-$6.94M$25.340.11

CervoMed has a beta of -0.62, meaning that its stock price is 162% less volatile than the broader market. Comparatively, Psyence Biomedical has a beta of 1.72, meaning that its stock price is 72% more volatile than the broader market.

25.2% of CervoMed shares are held by institutional investors. Comparatively, 77.4% of Psyence Biomedical shares are held by institutional investors. 35.8% of CervoMed shares are held by company insiders. Comparatively, 3.6% of Psyence Biomedical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, CervoMed and CervoMed both had 5 articles in the media. CervoMed's average media sentiment score of 0.44 beat Psyence Biomedical's score of 0.22 indicating that CervoMed is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
CervoMed
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Psyence Biomedical
0 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Psyence Biomedical's return on equity of 0.00% beat CervoMed's return on equity.

Company Net Margins Return on Equity Return on Assets
CervoMedN/A -164.95% -133.71%
Psyence Biomedical N/A N/A N/A

CervoMed currently has a consensus target price of $21.00, suggesting a potential upside of 1,478.95%. Given CervoMed's stronger consensus rating and higher possible upside, research analysts clearly believe CervoMed is more favorable than Psyence Biomedical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CervoMed
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.71
Psyence Biomedical
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

CervoMed beats Psyence Biomedical on 7 of the 13 factors compared between the two stocks.

How does Psyence Biomedical compare to ABVC BioPharma?

ABVC BioPharma (NASDAQ:ABVC) and Psyence Biomedical (NASDAQ:PBM) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.

Psyence Biomedical's return on equity of 0.00% beat ABVC BioPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
ABVC BioPharmaN/A -49.51% -30.84%
Psyence Biomedical N/A N/A N/A

Psyence Biomedical has lower revenue, but higher earnings than ABVC BioPharma. ABVC BioPharma is trading at a lower price-to-earnings ratio than Psyence Biomedical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ABVC BioPharma$510K46.55-$7.91M-$0.29N/A
Psyence BiomedicalN/AN/A-$6.94M$25.340.11

ABVC BioPharma has a beta of 0.47, indicating that its share price is 53% less volatile than the broader market. Comparatively, Psyence Biomedical has a beta of 1.72, indicating that its share price is 72% more volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ABVC BioPharma
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Psyence Biomedical
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Psyence Biomedical had 5 more articles in the media than ABVC BioPharma. MarketBeat recorded 5 mentions for Psyence Biomedical and 0 mentions for ABVC BioPharma. Psyence Biomedical's average media sentiment score of 0.22 beat ABVC BioPharma's score of 0.00 indicating that Psyence Biomedical is being referred to more favorably in the news media.

Company Overall Sentiment
ABVC BioPharma Neutral
Psyence Biomedical Neutral

11.4% of ABVC BioPharma shares are owned by institutional investors. Comparatively, 77.4% of Psyence Biomedical shares are owned by institutional investors. 19.0% of ABVC BioPharma shares are owned by insiders. Comparatively, 3.6% of Psyence Biomedical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Psyence Biomedical beats ABVC BioPharma on 8 of the 10 factors compared between the two stocks.

How does Psyence Biomedical compare to Polyrizon?

Polyrizon (NASDAQ:PLRZ) and Psyence Biomedical (NASDAQ:PBM) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, valuation, profitability, analyst recommendations, risk, dividends and earnings.

Company Net Margins Return on Equity Return on Assets
PolyrizonN/A N/A N/A
Psyence Biomedical N/A N/A N/A

Polyrizon has a beta of -1.16, suggesting that its stock price is 216% less volatile than the broader market. Comparatively, Psyence Biomedical has a beta of 1.72, suggesting that its stock price is 72% more volatile than the broader market.

77.4% of Psyence Biomedical shares are owned by institutional investors. 3.6% of Psyence Biomedical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PolyrizonN/AN/A-$3.34MN/AN/A
Psyence BiomedicalN/AN/A-$6.94M$25.340.11

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Polyrizon
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Psyence Biomedical
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Psyence Biomedical had 5 more articles in the media than Polyrizon. MarketBeat recorded 5 mentions for Psyence Biomedical and 0 mentions for Polyrizon. Psyence Biomedical's average media sentiment score of 0.22 beat Polyrizon's score of 0.00 indicating that Psyence Biomedical is being referred to more favorably in the news media.

Company Overall Sentiment
Polyrizon Neutral
Psyence Biomedical Neutral

Summary

Psyence Biomedical beats Polyrizon on 5 of the 6 factors compared between the two stocks.

How does Psyence Biomedical compare to MIRA Pharmaceuticals?

MIRA Pharmaceuticals (NASDAQ:MIRA) and Psyence Biomedical (NASDAQ:PBM) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, media sentiment, valuation and institutional ownership.

MIRA Pharmaceuticals is trading at a lower price-to-earnings ratio than Psyence Biomedical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MIRA PharmaceuticalsN/AN/A-$10.44M-$1.24N/A
Psyence BiomedicalN/AN/A-$6.94M$25.340.11

In the previous week, MIRA Pharmaceuticals and MIRA Pharmaceuticals both had 5 articles in the media. MIRA Pharmaceuticals' average media sentiment score of 0.45 beat Psyence Biomedical's score of 0.22 indicating that MIRA Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
MIRA Pharmaceuticals
0 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Psyence Biomedical
0 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

35.2% of MIRA Pharmaceuticals shares are owned by institutional investors. Comparatively, 77.4% of Psyence Biomedical shares are owned by institutional investors. 19.9% of MIRA Pharmaceuticals shares are owned by company insiders. Comparatively, 3.6% of Psyence Biomedical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

MIRA Pharmaceuticals presently has a consensus target price of $3.50, suggesting a potential upside of 850.31%. Given MIRA Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe MIRA Pharmaceuticals is more favorable than Psyence Biomedical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MIRA Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
Psyence Biomedical
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

MIRA Pharmaceuticals has a beta of 1.65, meaning that its stock price is 65% more volatile than the broader market. Comparatively, Psyence Biomedical has a beta of 1.72, meaning that its stock price is 72% more volatile than the broader market.

Psyence Biomedical's return on equity of 0.00% beat MIRA Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
MIRA PharmaceuticalsN/A -112.41% -108.40%
Psyence Biomedical N/A N/A N/A

Summary

Psyence Biomedical beats MIRA Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

How does Psyence Biomedical compare to Incannex Healthcare?

Psyence Biomedical (NASDAQ:PBM) and Incannex Healthcare (NASDAQ:IXHL) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, valuation, profitability, institutional ownership, earnings and analyst recommendations.

Psyence Biomedical's return on equity of 0.00% beat Incannex Healthcare's return on equity.

Company Net Margins Return on Equity Return on Assets
Psyence BiomedicalN/A N/A N/A
Incannex Healthcare N/A -20.27%-19.15%

Psyence Biomedical has a beta of 1.72, meaning that its share price is 72% more volatile than the broader market. Comparatively, Incannex Healthcare has a beta of 7, meaning that its share price is 600% more volatile than the broader market.

77.4% of Psyence Biomedical shares are owned by institutional investors. Comparatively, 0.4% of Incannex Healthcare shares are owned by institutional investors. 3.6% of Psyence Biomedical shares are owned by insiders. Comparatively, 9.1% of Incannex Healthcare shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Incannex Healthcare has a consensus target price of $18.00, indicating a potential upside of 934.48%. Given Incannex Healthcare's stronger consensus rating and higher possible upside, analysts clearly believe Incannex Healthcare is more favorable than Psyence Biomedical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Psyence Biomedical
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Incannex Healthcare
2 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.67

Psyence Biomedical has higher earnings, but lower revenue than Incannex Healthcare. Incannex Healthcare is trading at a lower price-to-earnings ratio than Psyence Biomedical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Psyence BiomedicalN/AN/A-$6.94M$25.340.11
Incannex Healthcare$90K242.63-$19.30M-$1.24N/A

In the previous week, Psyence Biomedical had 4 more articles in the media than Incannex Healthcare. MarketBeat recorded 5 mentions for Psyence Biomedical and 1 mentions for Incannex Healthcare. Incannex Healthcare's average media sentiment score of 3.00 beat Psyence Biomedical's score of 0.22 indicating that Incannex Healthcare is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Psyence Biomedical
0 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Incannex Healthcare
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

Summary

Incannex Healthcare beats Psyence Biomedical on 7 of the 13 factors compared between the two stocks.

Get Psyence Biomedical News Delivered to You Automatically

Sign up to receive the latest news and ratings for PBM and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PBM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PBM vs. The Competition

MetricPsyence BiomedicalPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$5.76M$13.27B$7.57B$11.65B
Dividend YieldN/A2.60%2.48%4.74%
P/E Ratio0.1127.1733.2128.18
Price / SalesN/A6.838.295.46
Price / CashN/A15.5320.7221.66
Price / Book0.395.284.423.65
Net Income-$6.94M$2.87B$3.51B$394.00M
7 Day Performance-8.92%-5.18%-5.53%-5.64%
1 Month Performance-32.55%-7.80%-8.70%-9.48%
1 Year Performance-73.40%-6.75%-1.44%-6.81%

Psyence Biomedical Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PBM
Psyence Biomedical
1.4599 of 5 stars
$2.86
+13.9%
N/A-83.6%$5.76MN/A0.1112
CRVO
CervoMed
2.7385 of 5 stars
$1.83
+3.4%
$21.00
+1,047.5%
-84.6%$26.78M$4.01MN/A15
ABVC
ABVC BioPharma
0.0509 of 5 stars
$0.96
-2.9%
N/A-67.6%$26.76M$510KN/A19
PLRZ
Polyrizon
0.4023 of 5 stars
$11.48
+4.2%
N/A+147.1%$26.76MN/AN/A1
MIRA
MIRA Pharmaceuticals
2.7615 of 5 stars
$0.65
+4.2%
$3.50
+439.9%
-73.7%$26.14MN/AN/A2

Related Companies and Tools


This page (NASDAQ:PBM) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners